| 0.889 0.018 (2.07%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.71 | 1-year : | 2.21 |
| Resists | First : | 1.47 | Second : | 1.89 |
| Pivot price | 1.02  |
|||
| Supports | First : | 0.77 | Second : | 0.64 |
| MAs | MA(5) : | 0.88 |
MA(20) : | 1 |
| MA(100) : | 0.96 |
MA(250) : | 1.32 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 2.2  |
D(3) : | 1.8 |
| RSI | RSI(14): 44.9 |
|||
| 52-week | High : | 3.33 | Low : | 0.75 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ INKT ] has closed above bottom band by 33.4%. Bollinger Bands are 236.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 14 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.93 - 0.93 | 0.93 - 0.94 |
| Low: | 0.85 - 0.85 | 0.85 - 0.86 |
| Close: | 0.88 - 0.89 | 0.89 - 0.9 |
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Mon, 08 Apr 2024
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases ... - Yahoo Finance
Mon, 08 Apr 2024
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases ... - GlobeNewswire
Mon, 25 Mar 2024
All You Need to Know About MiNK Therapeutics, Inc. (INKT) Rating Upgrade to Buy - Yahoo Finance
Fri, 22 Mar 2024
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Call Transcript - Yahoo Finance
Thu, 21 Mar 2024
MiNK Reports Fourth Quarter and Year-End 2023 Results - GlobeNewswire
Thu, 21 Mar 2024
INKT Stock Earnings: MiNK Therapeutics Misses EPS for Q4 2023 - InvestorPlace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 35 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 71.3 (%) |
| Held by Institutions | 2.9 (%) |
| Shares Short | 41 (K) |
| Shares Short P.Month | 41 (K) |
| EPS | -0.65 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.52 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -110.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.66 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -16 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -1.37 |
| PEG Ratio | 0 |
| Price to Book value | -1.71 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.96 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|